Jacob Orme

Keywords strategic isolation, putative COX enzyme, honors thesis College Physical and Mathematical Sciences Department Church History and Doctrine Abstract Most of the results of my work are confidential pending publication. This also applies to the public availability of my honors thesis, which will not be printed until later this year as a result.

Treatment with 177Lu-prostate-specific membrane antigen (PSMA)–617 (177Lu-vipivotide tetraxetan [Pluvicto]) prolongs both progression-free and overall survival in advanced PSMA-positive metastatic castration-resistant prostate cancer. Data examining specifically neurologic symptoms after 177Lu-PSMA-617 treatment are scarce. In this study, we aimed to review the neurologic findings in a large cohort of metastatic castration-resistant prostate cancer patients undergoing 177Lu-PSMA-617 therapy.

Treating prostate cancer with intensified androgen blockade is widely accepted.